Evidence Hub

Metallo-β-lactamase-producing Pseudomonas aeruginosa: epidemiology, diagnostic challenges and therapeutic strategies in the era of MDR/XDR resistance

Imeneo A, Capone A, Antonelli V, Perri V, Petriccione I, Lodi A, Fontana C, Cicalini S

Frontiers in microbiology, 2026

Abstract

Background: The management of multidrug-resistant (MDR) Pseudomonas aeruginosa has evolved from an antibiotic-centric approach to a mechanism-driven paradigm. Among resistance determinants, metallo-β-lactamases (MBLs) represent a critical challenge due to their ability to hydrolyse most β-lactams and their increasing global dissemination within high-risk clones.

Methods: This narrative review aims to summarize the epidemiology, diagnostic approaches and therapeutic strategies for infections caused by MBL-producing P. aeruginosa, emphasizing a mechanism-based clinical framework. A PubMed-MEDLINE search was conducted up to 1 June 2026 using the terms "Pseudomonas aeruginosa", "carbapenem resistance", and "metallo-β-lactamase". Relevant studies were selected based on the authors' assessment of methodological quality and clinical relevance.

Results: P. aeruginosa exhibits multifactorial resistance involving intrinsic mechanisms (efflux pumps, AmpC overexpression, porin loss), adaptive responses and acquired carbapenemases. MBLs, especially VIM, IMP, and emerging NDM variants, are increasingly associated with carbapenem resistance and epidemic high-risk clones (e.g., ST235, ST111). Global epidemiology shows marked geographic variability in prevalence and molecular types. Diagnostic workup remains challenging due to the coexistence of enzymatic and non-enzymatic mechanisms, requiring integrated use of phenotypic antibiotic susceptibility testing (AST), carbapenemase detection…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free